# VAX-31 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vax-31

> The next catalyst for VAX-31, sponsored by Vaxcyte, Inc. (PCVX), is its topline data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for VAX-31?

The next catalyst for VAX-31, sponsored by Vaxcyte, Inc. (PCVX), is its topline data readout, 1H 2027. Press release filed with the SEC (EX-99): "Enrollment in the modified study is expected to proceed by the end of the third quarter of this year with topline data from both the primary immunization series and the booster dose by the end of the first half of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/vax-31)

Source: Press release filed with the SEC (EX-99), accession 0001649094-25-000096, https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/vax-31#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | VAX-31 |
| Codes | VAX-31 |
| Sponsor | Vaxcyte, Inc. (PCVX) https://sec-api.dev/companies/pcvx/catalysts |
| Indications | invasive pneumococcal disease, disease caused, ipd in infants |
| Modality |  |
| FDA designations | breakthrough |

## Timeline

### Sep 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 1/2.
- First seen 2025-02-25, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001649094-26-000054): "•In September 2024, prior to the initiation of our VAX-31 adult Phase 3 program, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000054/pcvx-20260930.htm
- SEC Form 10-Q (accession 0001649094-26-000043): "•In September 2024, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000043/pcvx-20260630.htm
- SEC Form 10-Q (accession 0001649094-26-000017): "•In September 2024, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000017/pcvx-20260331.htm
- SEC Form 10-K (accession 0001649094-26-000007): "•In September 2024, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm
- SEC Form 10-K (accession 0001649094-26-000007): "For VAX-31, we achieved clinical proof of concept in September 2024 when we announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31 in healthy adults aged 50 and older." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm
- SEC Form 10-Q (accession 0001649094-25-000114): "•In September 2024, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000114/pcvx-20250930.htm
- SEC Form 10-Q (accession 0001649094-25-000098): "•In September 2024, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000098/pcvx-20250630.htm
- SEC Form 10-Q (accession 0001649094-25-000074): "•In September 2024, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000074/pcvx-20250331.htm
- SEC Form 10-K (accession 0001649094-25-000028): "•In September 2024, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm
- SEC Form 10-K (accession 0001649094-25-000028): "▪Following the positive topline data from the VAX-31 adult Phase 1/2 study announced in September 2024, we selected VAX-31 to exclusively advance to an adult Phase 3 program, and plan to select the dose prior to the initiation of such program." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm
- SEC Form 10-K (accession 0001649094-25-000028): "For VAX-31, we achieved clinical proof of concept in September 2024 when we announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31 in healthy adults aged 50 and older." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm
- SEC Form 10-K (accession 0001649094-25-000028): "•Reported Positive Topline Data from Phase 1/2 Study of VAX-31 in Adults Aged 50 and Older: In September 2024, we announced positive topline results from the Phase 1/2 clinical study evaluating the safety, tolerability and immunogenicity of VAX-31 in 1,015 healthy adults aged 50 and older." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: IPD in Infants.
- First seen 2025-02-25, last confirmed 2025-02-25.
- SEC Form 10-K (accession 0001649094-25-000028): "•Initiated Phase 2 Study Evaluating VAX-31 for the Prevention of IPD in Infants: In December 2024, we announced the initiation of the Phase 2 study of VAX-31 in healthy infants and that the first study participants have been dosed." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-02-25, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000073): "-- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 --" https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx20250507-exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000027): "-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 --" https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000027): ""For the adult indication, we remain on track to initiate the VAX-31 adult Phase 3 pivotal, non-inferiority study by mid-2025, with topline data expected in 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225xexx991.htm
- SEC Form 10-K (accession 0001649094-25-000028): "Following an FDA VAX-31 End-of-Phase 2 meeting, we plan to initiate a Phase 3 pivotal, non-inferiority study by mid-2025 and announce topline safety, tolerability and immunogenicity data in 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm
- SEC Form 10-K (accession 0001649094-25-000028): "We plan to initiate remaining VAX-31 Phase 3 studies in 2025 and 2026 and announce data from these studies in 2026 and 2027." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm

### August 6, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-08-06, last confirmed 2025-08-06.
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000096): "Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)" https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm

### Dec 2025: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: invasive pneumococcal disease.
- First seen 2025-08-06, last confirmed 2026-02-24.
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000005): "•Initiated OPUS-1, the Pivotal Phase 3 Noninferiority Trial: In December 2025, the Company dosed the first participants in the OPUS-1 trial evaluating VAX-31 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000005): "•Initiated OPUS-2 and OPUS-3 Phase 3 Trials in Key Adult Populations: In January 2026, the Company dosed the first participants in OPUS-2, a Phase 3 descriptive study designed to evaluate the safety, tolerability and immunogenicity of VAX-31 when administered concomitantly with, or one month following, a licensed, high-dose seasonal influenza vaccine in approximately 1,300 pneumococcal-naïve1 adults aged 50 years and older." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm
- SEC Form 10-K (accession 0001649094-26-000007): "•Initiated Phase 3 OPUS-2 and OPUS-3 Trials: In January 2026, we dosed the first participants in OPUS-2, a Phase 3 descriptive study designed to evaluate the safety, tolerability and immunogenicity of VAX-31 when administered concomitantly with, or one month following, a licensed, high-dose seasonal influenza vaccine in approximately 1,300 pneumococcal-naïve adults aged 50 years and older (defined as having no known prior history of IPD, pneumococcal pneumonia, or receipt of any licensed or investigational pneumococcal vaccine)." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm
- SEC Form 10-K (accession 0001649094-26-000007): "Following an FDA End-of-Phase 2 meeting, we initiated a Phase 3 pivotal, non-inferiority study in December 2025 and expect to announce topline safety, tolerability and immunogenicity data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm
- SEC Form 10-K (accession 0001649094-26-000007): "•Initiated Phase 3 OPUS-1 Trial: In December 2025 we announced we dosed the first participants in the OPUS-1 trial, with topline data expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000112): "Company Expects to Initiate VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with Topline Data in 2026" https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx20251104-exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000096): "•Initiate the Phase 3 pivotal, non-inferiority study in the fourth quarter of 2025 and announce topline safety, tolerability and immunogenicity data in 2026, consistent with prior readout guidance." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm
- SEC Form 10-Q (accession 0001649094-25-000114): "We plan to initiate the Phase 3 pivotal, non-inferiority study in December 2025 and announce topline safety, tolerability and immunogenicity data from this study in 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000114/pcvx-20250930.htm

### 2026: NDA/BLA submission

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-08-06, last confirmed 2025-08-06.
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000096): "We look forward to delivering multiple anticipated Phase 3 data readouts in 2026 and 2027 to support our potential BLA submission for the VAX-31 adult indication." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm

### mid-2026: topline data readout

- Status: delayed. Date confidence: half. Stage: 2.
- First seen 2025-02-25, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-067901): "Based on these findings, the Company has selected the VAX-24 Mid dose as the basis for advancement of an optimized dose formulation to a potential Phase 3 program and, pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026, plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31." https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000027): "We also recently advanced the VAX-31 infant Phase 2 study to the second and final stage and expect topline data for the primary immunization series in mid-2026."" https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225xexx991.htm
- SEC Form 10-K (accession 0001649094-25-000028): "We plan to announce topline safety, tolerability and immunogenicity data from the ongoing VAX-31 infant Phase 2 study primary three-dose immunization series in mid-2026, followed by topline data from the booster dose approximately nine months later." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000073): "For the pediatric indication, we expect to announce the balance of the VAX-24 infant Phase 2 dose-finding study data by the end of 2025 and share topline data from the VAX-31 infant Phase 2 dose-finding study primary immunization series in mid-2026, followed by complete booster data up to nine months later." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx20250507-exx991.htm
- SEC Form 10-K (accession 0001649094-25-000028): "We expect to announce topline data from the Phase 2 primary three-dose immunization series in mid-2026, followed by topline data from the booster dose approximately nine months later." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm
- SEC Form 10-Q (accession 0001649094-25-000074): "We expect to share topline data from the primary three-dose immunization series of the study in mid-2026, with complete booster data up to nine months later." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000074/pcvx-20250331.htm
- SEC Form 10-K (accession 0001649094-25-000028): "We expect to share topline data from the primary three-dose immunization series of the study in mid-2026, followed by topline data from the booster dose approximately nine months later." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm

### mid-2026: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-11-04, last confirmed 2026-05-06.
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000015): "Company Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1, a Vaccine Candidate to Prevent Disease Caused by Group A Strep, in Mid-2026" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000015): "Advancing VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Universal Protection Against Disease Caused by Group A Strep, into the Clinic: In mid-2026, the Company plans to initiate a Phase 1 adult study for its most advanced preclinical program, VAX-A1, a prophylactic vaccine candidate designed to prevent disease caused by Group A Strep (Streptococcus pyogenes), with the primary objective of assessing safety and tolerability, along with a secondary objective of evaluating initial immunogenicity data, to support potential further advancement." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000112): ""For the adult indication, we expect to initiate the VAX-31 pivotal, non-inferiority study in December, with additional Phase 3 study initiations in 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx20251104-exx991.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-08-06, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000015): "Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000005): "Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm
- SEC Form 10-Q (accession 0001649094-26-000043): "We expect to announce topline safety, tolerability and immunogenicity data from this study in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000043/pcvx-20260630.htm
- SEC Form 10-Q (accession 0001649094-26-000017): "We expect to announce topline safety, tolerability and immunogenicity data from this study in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000017/pcvx-20260331.htm
- SEC Form 10-K (accession 0001649094-26-000007): "We expect to announce topline safety, tolerability and immunogenicity data from this study in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000041): ""We are on track to deliver the topline data from the OPUS-1 noninferiority trial in the fourth quarter of this year." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000112): "Company Expects to Initiate VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with Topline Data in 2026" https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx20251104-exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000096): "This work includes final-stage planning for the pivotal, non-inferiority study, which we intend to initiate in the fourth quarter of this year with topline data expected in 2026, consistent with prior readout guidance." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000096): "This includes conducting final-stage planning for the pivotal, non-inferiority study, which is expected to be initiated in the fourth quarter of this year, with topline data expected in 2026, consistent with prior readout guidance." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm
- SEC Form 10-Q (accession 0001649094-25-000114): "This includes conducting final-stage planning for the pivotal, non-inferiority study, which is expected to be initiated in December 2025, with topline data expected in 2026, consistent with prior readout guidance." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000114/pcvx-20250930.htm
- SEC Form 10-Q (accession 0001649094-25-000098): "This includes conducting final-stage planning for the pivotal, non-inferiority study, which is expected to be initiated in the fourth quarter of this year, with topline data expected in 2026, consistent with prior readout guidance." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000098/pcvx-20250630.htm

### October 5, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-02-25, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-413168): "SAN CARLOS, Calif., October 5, 2026 - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia." https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000051): "Reported Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31: In October 2026, the Company announced positive topline results from OPUS-1, which evaluated the safety, tolerability and immunogenicity of VAX-31, its next-generation 31-valent PCV candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm
- SEC Form 10-Q (accession 0001649094-26-000054): "•In October 2026, we announced positive topline results from the pivotal adult Phase 3 trial of VAX-31 ("OPUS-1")." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000054/pcvx-20260930.htm
- SEC Form 10-Q (accession 0001649094-26-000054): "•Reported Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31: In October 2026, we announced positive results from the OPUS-1 trial." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000054/pcvx-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-417977): "On October 5, 2026, we announced positive topline results from the Phase 3 OPUS-1 trial." https://www.sec.gov/Archives/edgar/data/1649094/000119312526417977/d176371d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-417984): "On October 5, 2026, we announced positive topline results from the Phase 3 OPUS-1 trial." https://www.sec.gov/Archives/edgar/data/1649094/000119312526417984/d177446d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-414774): "On October 5, 2026, we announced positive topline results from the Phase 3 OPUS-1 trial." https://www.sec.gov/Archives/edgar/data/1649094/000119312526414774/d177446d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000041): "Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000073): "-- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 --" https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx20250507-exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-067901): "For the adult indication, the VAX-31 Phase 3 non-interiority study initiation is expected in mid-2025 with topline data in 2026." https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000027): "-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 --" https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000027): ""For the adult indication, we remain on track to initiate the VAX-31 adult Phase 3 pivotal, non-inferiority study by mid-2025, with topline data expected in 2026." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225xexx991.htm

### 1H 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-08-06, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000096): "Enrollment in the modified study is expected to proceed by the end of the third quarter of this year with topline data from both the primary immunization series and the booster dose by the end of the first half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000096): "We expect the modified study to proceed by the end of the third quarter of this year with topline data from both the primary immunogenicity series and the booster dose expected by the end of the first half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm
- SEC Form 10-K (accession 0001649094-26-000007): "We expect to announce topline safety, tolerability and immunogenicity data from the primary three-dose immunization series and booster dose either sequentially or together by the end of the first half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm
- SEC Form 10-Q (accession 0001649094-25-000114): "We expect to announce topline data from the primary immunization series and the booster dose either sequentially or together by the end of the first half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000114/pcvx-20250930.htm
- SEC Form 10-Q (accession 0001649094-25-000098): "Enrollment in the modified study is expected to proceed by the end of the third quarter of this year with topline data from both the primary immunization series and the booster dose by the end of the first half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000098/pcvx-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000051): "VAX-31 Infant Indication: Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000051): "For the VAX-31 infant indication, we expect to announce topline data from the primary immunization series and booster dose of the ongoing Phase 2 study, either sequentially or together, by the end of the first half of 2027."" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000041): "Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000015): "Enrollment Completed for VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000005): "Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Expected Either Sequentially or Together by End of First Half of 2027" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001649094-25-000096): "•Announce topline safety, tolerability and immunogenicity data for the Phase 2 randomized, dose-finding study from both the primary three-dose immunization series and booster dose by the end of the first half of 2027, representing a minor extension to prior readout guidance." https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1. Indication: Disease Caused.
- First seen 2026-08-05, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000041): "Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults; Topline Data Expected in Second Half of 2027" https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805xexx991.htm
- SEC Form 10-Q (accession 0001649094-26-000054): "We expect to report topline data from this study in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000054/pcvx-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-417977): "We expect to report topline data from this study in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000119312526417977/d176371d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-417984): "We expect to report topline data from this study in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000119312526417984/d177446d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-414774): "We expect to report topline data from this study in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000119312526414774/d177446d424b5.htm
- SEC Form 10-Q (accession 0001649094-26-000043): "We expect to report topline data from this study in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000043/pcvx-20260630.htm

### 1H 2028: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-11-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001649094-26-000051): "With OPUS-1 serving as the foundation of our planned Biologics License Application (BLA), we remain on track to announce results from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of next year and, together with a manufacturing consistency study, we expect to submit a BLA in the first half of 2028." https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vax-31.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VAX-31 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vax-31

```bibtex
@misc{secapidev_pdufa_vax_31_20261116,
  title        = {VAX-31 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vax-31}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vax_31_20261116","title":"VAX-31 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vax-31","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
